Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

KPTI
Karyopharm Therapeutics Inc.
stock NASDAQ

At Close
Jul 30, 2026 3:59:57 PM EDT
6.99USD+1.968%(+0.13)1,603,964
6.04Bid   8.40Ask   2.36Spread
Pre-market
Jul 30, 2026 9:28:30 AM EDT
6.99USD+1.822%(+0.13)469
After-hours
Jul 30, 2026 4:59:30 PM EDT
2.77USD-60.400%(-4.22)652,584
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
07:18AM EST  Karyopharm Receives FDA's Orphan Drug Designation For   RTTNews
07:11AM EST  Karyopharm Receives Orphan Drug Designation From FDA For Eltanexor For Treatment Of Myelodysplastic Syndromes   RTTNews
07:03AM EST  Karyopharm Receives Orphan Drug Designation From FDA For Eltanexor For The Treatment Of Myelodysplastic Syndromes   Benzinga
07:01AM EST  Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the   PR Newswire
Jan 21, 2022
07:01AM EST  Karyopharm to Present at B. Riley Securities Oncology Investor Conference   PR Newswire
Jan 19, 2022
03:00PM EST  Karyopharma Shares Recently Spiked Higher; Hearing Co. Granted Orphan Drug Status For Its Myelodysplastic Syndrome Treatment   Benzinga
Jan 10, 2022
11:14AM EST  SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Raises Price Target to $8   Benzinga
07:57AM EST  Karyopharm Therapeutics Expects Q4 Net Product Revenues of XPOVIO to be $29.7M   Benzinga
07:13AM EST  Karyopharm Expects Net Product Revenues Of XPOVIO To Be About $29.7 Mln For Q4   RTTNews
07:06AM EST  Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer   PR Newswire
07:01AM EST  Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021   PR Newswire
Jan 4, 2022
07:01AM EST  Karyopharm to Present at 40th Annual J.P. Morgan Healthcare Conference   PR Newswire
Jan 3, 2022
04:06PM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Dec 21, 2021
08:57AM EST  Karyopharm And Menarini To Commercialize NEXPOVIO In Europe And Other Key Global Territories   RTTNews
08:52AM EST  Commercialize NEXPOVIO(r) (selinexor) in Europe and Other Key Global Territories   PR Newswire
07:55AM EST  Menarini Group To Commercialize Karyopharm's NEXPOVIO In   RTTNews
07:33AM EST  Karyopharm And Menarini Group To Commercialize NEXPOVIO In Europe And Other Key Global Territories   RTTNews
07:31AM EST  Karyopharm And Menarini Group Enter Into Exclusive License Agreement To Commercialize NEXPOVIO In Europe And Other Key Global Territories; Karyopharm To Receive Upfront Payment Of $75M   Benzinga
07:31AM EST  Commercialize NEXPOVIO(r) (selinexor) in Europe and Other Key Global Territories   PR Newswire
Dec 17, 2021
08:44AM EST  Antengene Receives Approval In China For XPOVIO For   RTTNews
08:38AM EST  Karyopharm Reports Its Partner Antengene Receives Approval In China For XPOVIO For Treatment Of Patients With Relapsed, Refractory Multiple Myeloma   Benzinga
08:37AM EST  (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma   PR Newswire
Dec 11, 2021
12:09PM EST  Karyopharm Announces Presentation Of Updated Phase 2 Selinexor Data In Patients With Myelofibrosis   RTTNews
12:00PM EST  with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition   PR Newswire
Dec 9, 2021
09:45PM EST  RBC Capital Maintains Sector Perform on Karyopharm Therapeutics, Raises Price Target to $9   Benzinga
Dec 6, 2021
04:39PM EST  Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways   Benzinga
04:09PM EST  Karyophar Appoints Peter Honig To Its Board Of Directors   RTTNews
04:06PM EST  Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of   PR Newswire
07:08AM EST  Karyopharm :First Patient Dosed In Phase 2 Study Evaluating Selinexor Versus Physician's Choice In Myelofibrosis   RTTNews
07:03AM EST  Karyopharm Announces Dosing Of First Patient In A New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice In Previously Treated Myelofibrosis   Benzinga
07:01AM EST  Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis   PR Newswire
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 3, 2021
05:35AM EST  Karyopharm Therapeutics Was Granted FDA Orphan Drug Designation on Thursday for Selinexor for Treatment of Glioblastoma   Benzinga
Dec 2, 2021
07:14AM EST  Karyopharm Completes Patient Recruitment In Phase 3 SIENDO Study Of Selinexor In Patients With Endometrial Cancer   RTTNews
07:01AM EST  Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor   PR Newswire
Dec 1, 2021
04:05PM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
07:01AM EST  Karyopharm to Host Virtual Investor Day on December 8, 2021   PR Newswire
Nov 19, 2021
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
07:18AM EST  Morgan Stanley Downgrades Karyopharm Therapeutics to Equal-Weight, Lowers Price Target to $10   Benzinga
Nov 11, 2021
07:01AM EST  Karyopharm to Participate at Jefferies London Healthcare Conference   PR Newswire
Nov 4, 2021
10:31AM EDT  Karyopharm Announces New Interim Phase 2 Selinexor Data In Myelofibrosis Selected For Oral Presentation At American Society Of Hematology 2021 Annual Meeting And Exposition   Benzinga
10:31AM EDT  Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition   PR Newswire
Nov 3, 2021
02:37PM EDT  Mid-Afternoon Market Update: Nasdaq Rises 60 Points; Federal Reserve Slows Down Bond Buying   Benzinga
12:15PM EDT  Mid-Day Market Update: Crude Oil Drops Over 3%; R.R.Donnelley & Sons Shares Jump   Benzinga
12:07PM EDT  Karyopharm Therapeutics Earnings Perspective: Return On Capital Employed   Benzinga
09:15AM EDT  Karyopharm Therapeutics Q3 EPS $(0.69) Misses $(0.67) Estimate, Sales $37.69M Beat $25.80M Estimate   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
07:16AM EDT  Karyopharm Q3 Loss/shr Narrows To $0.69 From $0.73 Last Year   RTTNews
07:02AM EDT  Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides   PR Newswire
Nov 1, 2021
04:06PM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Oct 27, 2021
07:01AM EDT  Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021   PR Newswire
Oct 21, 2021
12:11PM EDT  Karyopharm Announces Dosing Of First Patient In A Phase 2 Study Investigating Oral Eltanexor In HMA Refractory Myelodysplastic Syndrome   Benzinga
08:13AM EDT  Karyopharm Reports Dosing Of First Patient In Phase 2 Study Oral Eltanexor In HMA Refractory Myelodysplastic Syndrome   RTTNews
08:02AM EDT  Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating   PR Newswire
Oct 12, 2021
12:21PM EDT  What 4 Analyst Ratings Have To Say About Karyopharm Therapeutics   Benzinga
08:30AM EDT  Morgan Stanley Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $27   Benzinga
Oct 1, 2021
04:05PM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Sep 7, 2021
07:01AM EDT  Karyopharm Announces Upcoming Virtual Investor Conference Participation   PR Newswire
Sep 1, 2021
07:08AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
07:01AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
07:31AM EDT  Cramer Shares His Thoughts On Moderna, Nvidia And More   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 6, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021   Benzinga
07:56AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
06:07AM EDT  HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $26   Benzinga
05:38AM EDT  SVB Leerink Downgrades Karyopharm Therapeutics to Market Perform, Announces $6 Price Target   Benzinga
05:24AM EDT  RBC Capital Downgrades Karyopharm Therapeutics to Sector Perform, Lowers Price Target to $8   Benzinga
05:23AM EDT  JP Morgan Downgrades Karyopharm Therapeutics to Underweight   Benzinga
Aug 5, 2021
06:31PM EDT  Karyopharm Therapeutics S-8 Filing Shows Registration For 150K Share Common Stock Offering Via Selling Shareholders   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:24AM EDT  Karyopharm Q2 Loss/shr Widens To $0.71 From $0.63 Last Year   RTTNews
07:20AM EDT  Karyopharm Therapeutics Q2 EPS $(0.71) Beats $(0.74) Estimate, Net PRoduct Revenue $20.2M   Benzinga
07:02AM EDT  Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results   PR Newswire
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:01AM EDT  Karyopharm Announces Upcoming Virtual Investor Conference Participation   PR Newswire
Aug 2, 2021
07:01AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
07:02AM EDT  Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021   PR Newswire
Jul 28, 2021
07:22AM EDT  Karyopharm Unveils Dosing Of First Patients In Two New Co.-Sponsored Clinical Studies In Melanoma And Myelofibrosis   RTTNews
07:17AM EDT  Karyopharm Announces Dosing Of First Patients In Two New Company-Sponsored Clinical Studies In Melanoma And Myelofibrosis   Benzinga
07:02AM EDT  Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored   PR Newswire
Jul 1, 2021
08:08AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
08:01AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
07:18AM EDT  Karyopharm Expands Royalty Agreement With Healthcare Royalty For Up To $100 Mln   RTTNews
07:03AM EDT  Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100M   Benzinga
07:01AM EDT  Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For   PR Newswire
Jun 14, 2021
01:22PM EDT  Karyopharm Therapeutics Posts Study Titled 'Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma' To ClinicalTrials.Gov Site   Benzinga
Jun 9, 2021
01:49PM EDT  Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder   Benzinga
07:18AM EDT  Karyopharm To Present XPOVIO Data At EHA 2021 Virtual Congress   RTTNews
07:09AM EDT  Karyopharm Announces XPOVIO Data to be Presented at the European Hematology Association 2021 Virtual Congress   Benzinga
07:01AM EDT  Karyopharm Announces XPOVIO(r) (selinexor) Data to be Presented at the European   PR Newswire
Jun 8, 2021
08:33PM EDT  Karyopharm Therapeutics Announces Updated Data Of Eltanexor In Patients With Hypomethylating Agent Refractory MDS   RTTNews
08:00PM EDT  Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor   PR Newswire
04:01PM EDT  Karyopharm Announces Key Changes to Its Commercial Leadership Team   PR Newswire
Jun 3, 2021
07:07AM EDT  Karyopharm Announces XPOVIO Is Now Available In Additional Strength Tablets   RTTNews
07:01AM EDT  Karyopharm Announces XPOVIO(r) (selinexor) Is Now Available in Additional   PR Newswire
Jun 2, 2021
07:26AM EDT  Karyopharm Gets Conditional Marketing Authorization In UK For NEXPOVIO In Combination With Dexamethasone   RTTNews
07:15AM EDT  Karyopharm Receives Conditional Marketing Authorization in the United Kingdom for NEXPOVIO in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma   Benzinga
07:01AM EDT  (UK) for NEXPOVIO(r) (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma   PR Newswire
Jun 1, 2021
04:02PM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
May 26, 2021
08:01AM EDT  Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference   PR Newswire
07:06AM EDT  Karyopharm Announces Open Enrollment At Participating Hospitals In Europe For A Phase 3 Maintenance Study Evaluating Selinexor In Patients With Endometrial Cancer After Combination Chemotherapy   Benzinga
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:01PM EDT  Karyopharm Announces XPOVIO(r) (selinexor) Data to be Presented at the 2021   PR Newswire
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
08:28AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
08:03AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
May 3, 2021
12:54PM EDT  SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $15   Benzinga
07:15AM EDT  Karyopharm Q1 Net Loss Per Share $0.77 Vs Net Loss Per Share $0.78 Last Year   RTTNews
07:10AM EDT  Karyopharm Therapeutics Q1 EPS $(0.77) Misses $(0.71) Estimate, Sales $23.26M Miss $25.17M Estimate   Benzinga
07:09AM EDT  Karyopharm Therapeutics Announces Richard Paulson President and CEO   Benzinga
07:05AM EDT  Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent   PR Newswire
07:02AM EDT  Karyopharm Therapeutics Appoints Richard Paulson As President And CEO, Effective May 3, 2021   RTTNews
07:01AM EDT  Karyopharm Announces the Appointment of Richard Paulson as President and Chief   PR Newswire
04:13AM EDT  Earnings Scheduled For May 3, 2021   Benzinga
Apr 30, 2021
10:23AM EDT  Earnings Preview: Karyopharm Therapeutics   Benzinga
Apr 28, 2021
07:01AM EDT  Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021   PR Newswire
Apr 26, 2021
07:24AM EDT  Karyopharm: EMA Validates Type II Variation MAA For NEXPOVIO With Velcade And Dexamethasone   RTTNews
07:11AM EDT  Karyopharm Announces European Medicines Agency Validation Of Type II Variation Marketing Authorization Application For NEXPOVIO In Combination With Velcade And Dexamethasone For Adult Patients With Multiple Myeloma   Benzinga
07:01AM EDT  Variation Marketing Authorization Application for NEXPOVIO(r) (selinexor) in Combination with Velcade(r) (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma   PR Newswire
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
10:18AM EDT  Stocks That Hit 52-Week Lows On Monday   Benzinga
07:27AM EDT  Karyopharm Announces Publication Of Health-Related Quality Of Life Outcomes From Phase 3 SEAL Study Of Selinexor   RTTNews
07:04AM EDT  Karyopharm Therapeutics Publishes Quality of Life Outcomes from its Phase 3 SEAL Study of Selinexor in Publication Future Oncology   Benzinga
07:01AM EDT  from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology   PR Newswire
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 6, 2021
07:33AM EDT  Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings   Benzinga
05:37AM EDT  Antengene Announced NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma; ATG-019 is an Oral Dual PAK4/NAMPT Inhibitor Developed by Karyopharm Therapeutics   Benzinga
Apr 1, 2021
08:02AM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 29, 2021
02:27PM EDT  Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer   Benzinga
12:53PM EDT  Karyopharm Shares Spike Higher After Announcement Co. Receives Conditional Market Authorization From The European Commission For NEXPOVIO (selinexor)   Benzinga
12:50PM EDT  Commission for NEXPOVIO(r) (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma   PR Newswire
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 10, 2021
09:13AM EST  Karyopharm Therapeutics Says Expanded Partnership With Medidata Supports Co's Mission To Develop First-In-Class Therapeutics   Benzinga
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 2, 2021
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
Mar 1, 2021
04:06PM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Feb 24, 2021
07:09AM EST  Karyopharm's Partner Antengene Receives Priority Review For Selinexor Application In China   Benzinga
Feb 17, 2021
04:06PM EST  Karyopharm Announces Upcoming Virtual Investor Conference Participation   PR Newswire
Feb 12, 2021
10:50PM EST  KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI   Business Wire
Feb 11, 2021
11:21AM EST  SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $22   Benzinga
10:34AM EST  Karyopharma Therapeutics shares were trading higher after the company reported better-than-expected Q4 sales results.   Benzinga
08:01AM EST  Karyopharm Q4 Net Loss $43.4 Mln Or $0.59/shr Vs Net Loss $48.6 Mln Or $0.76/shr Prior Year   RTTNews
07:01AM EST  Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and   PR Newswire
03:51AM EST  Earnings Scheduled For February 11, 2021   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 4, 2021
09:03AM EST  Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on   PR Newswire
07:54AM EST  Karyopharm's XPOVIO Gets Regulatory Approval In Israel For Treatment Of Patients With Multiple Myeloma And DLBCL   RTTNews
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
07:20AM EST  Karyopharm Announces XPOVIO Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma   Benzinga
07:01AM EST  Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma   PR Newswire
Feb 1, 2021
04:05PM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Jan 29, 2021
10:50PM EST  Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI   PR Newswire
08:41AM EST  Karyopharm Receives Positive CHMP Opinion For NEXPOVIO For Treatment Of Patients With Refractory Multiple Myeloma   Benzinga
08:40AM EST  Karyopharm Gets Positive CHMP Opinion For NEXPOVIO For Treatment Of Patients With Refractory Multiple Myeloma   RTTNews
08:39AM EST  Karyopharm Receives Positive CHMP Opinion for NEXPOVIO(r) (selinexor) for the   PR Newswire
Jan 12, 2021
05:14AM EST  SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $25   Benzinga
Jan 11, 2021
08:30AM EST  Karyopharm Expects Q4 Total Revenues To Be $35.0 Mln - $36.0 Mln   RTTNews
08:06AM EST  Karyopharm Sees Prelim. Q4 Sales $35M-$36M vs $24.91M Est., Sees Prelim. FY20 Sales $108M-$109M vs $98.14M Est.   Benzinga
08:01AM EST  Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020   PR Newswire
Jan 5, 2021
05:20AM EST  Karyopharm Therapeutics Partner Antengene Announced Monday Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer   Benzinga
Jan 4, 2021
04:06PM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Benzinga
04:05PM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
07:01AM EST  Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference   PR Newswire
Jan 3, 2021
07:00PM EST  Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and   PR Newswire
Dec 20, 2020
10:09PM EST  Antengene Corporation Limited said that its U.S. Partner, Karyopharm Therapeutics Inc. (KPTI), received an approval from the U.S. Food and Drug Administration for oral Xpovio drug, in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.   RTTNews
07:50PM EST  Karyopharm Therapeutics Gets FDA Approval Of XPOVIO As Treatment For Patients With Multiple Myeloma   RTTNews
07:00PM EST  received FDA Approval of XPOVIO(r) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy   PR Newswire
Dec 18, 2020
10:50PM EST  KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI   Business Wire
11:35AM EST  Karyopharm Announces FDA Approval Of XpovioAs A Treatment For Patients With Multiple Myeloma After At Least One Prior Therapy   Benzinga
11:31AM EST  Karyopharm Announces FDA Approval of XPOVIO(r) (Selinexor) as a Treatment for   PR Newswire
Dec 15, 2020
07:15AM EST  Karyopharm Therapeutics Appoints Michael Mano As SVP, General Counsel   RTTNews
07:01AM EST  Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and   PR Newswire
Dec 11, 2020
11:09AM EST  Karyopharma Reports National Comprehensive Cancer Network Adds 3 XPOVIO Treatment Regimens To Clinical Practice Guidelines In Oncology For Multiple Myeloma   Benzinga
11:08AM EST  XPOVIO(r) (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma   PR Newswire
Dec 7, 2020
04:07PM EST  Karyopharm Announces Presentation of New XPOVIO Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting   Benzinga
04:05PM EST  with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting   PR Newswire
01:33PM EST  Karyopharm Presents XPOVIO Data In Multiple Myeloma And Diffuse Large-B-Cell Lymphoma At ASH 2020   Benzinga
01:31PM EST  Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting   PR Newswire
06:59AM EST  Karyopharm Therapeutics Partner Antengene Announced Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study   Benzinga
Dec 1, 2020
04:05PM EST  Karyopharm Announces Investor and Analyst Event at the American Society of   PR Newswire
07:51AM EST  Karyopharm Appoints Chen Schor To Its Board, Stephen Mitchener Chief Business Officer   RTTNews
07:01AM EST  Karyopharm Expands Board of Directors and Executive Leadership Team and Reports   PR Newswire
Nov 25, 2020
07:35AM EST  The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback   Benzinga
07:06AM EST  Karyopharm : DSMB Recommends Phase 3 Study On Endometrial Cancer Should Proceed As Planned Without Any Modifications   RTTNews
07:00AM EST  Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modifications   PR Newswire
Nov 20, 2020
10:31AM EST  Karyopharm Therapeutics Reports Phase 3 SEAL Data In Oral Presentation At Connective Tissue Oncology Society 2020 Annual Meeting: 'Twice-Weekly XPOVIO (selinexor) Demonstrates a Statistically Significant Improvement in Median PFS...'   Benzinga
10:30AM EST  Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The   PR Newswire
08:06AM EST  The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger   Benzinga
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
06:06AM EST  Karyopharm Announced Publication of Positive PXPOVIO (Selinexor) Phase 3 BOSTON Study Results in The Lancet   Benzinga
Nov 12, 2020
07:56PM EST  Karyopharm Announces Publication Of XPOVIO Phase 3 BOSTON Study Results   RTTNews
07:07PM EST  Karyopharm Announces Publication of XPOVIO(r) (Selinexor) Phase 3 BOSTON Study   PR Newswire
Nov 10, 2020
07:01AM EST  Karyopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference   PR Newswire
Nov 4, 2020
01:17PM EST  Karyopharma Reports XPOVIO Data To Be Presented At American Society Of Hematology Dec. 5, 6, 7   Benzinga
01:17PM EST  Karyopharm Announces XPOVIO(r) (Selinexor) Clinical Data to be Presented at the   PR Newswire
Nov 3, 2020
01:12PM EST  Karyopharm Therapeutics shares are trading higher after the company announced the Phase 3 SEAL study met its primary endpoint.   Benzinga
08:45AM EST  Morgan Stanley Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $32   Benzinga
08:11AM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
08:01AM EST  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
04:11AM EST  SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $28   Benzinga
Nov 2, 2020
04:41PM EST  Karyopharm Therapeutics: Q3 Earnings Insights   Benzinga
04:17PM EST  Karyopharm Therapeutics Q3 EPS $(0.73) Misses $(0.72) Estimate, Sales $21.30M Miss $21.45M Estimate   Benzinga
04:16PM EST  Karyopharm Shares Were Halted With News Pending; Reported Phase 3 SEAL Study Met Primary Endpoint; Shares To Resume Trade At 4:35 p.m. EST   Benzinga
04:06PM EST  Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent   PR Newswire
04:02PM EST  Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma   PR Newswire
07:55AM EST  Earnings Scheduled For November 2, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 26, 2020
07:01AM EDT  Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020   PR Newswire
Oct 20, 2020
10:01AM EDT  Karyopharm Therapeutics Selects MediSpend's Transparency Solution   PR Newswire
Oct 19, 2020
04:01PM EDT  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.   GlobeNewswire Inc
Oct 6, 2020
08:15AM EDT  Karyopharm Reveals Promising Results On Low Dose Selinexor In Hospitalized Patients With Severe COVID-19   RTTNews
08:01AM EDT  Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19   Benzinga
08:01AM EDT  International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19   PR Newswire
Oct 1, 2020
04:05PM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Sep 14, 2020
09:44AM EDT  Karyopharm Announces XPOVIO Clinical Data To Be Presented At European Society For Medical Oncology Virtual Congress 2020   Benzinga
09:43AM EDT  Karyopharm Announces XPOVIO(r) (selinexor) Clinical Data to be Presented at   PR Newswire
Sep 2, 2020
07:01AM EDT  Karyopharm Announces September 2020 Virtual Investor Conference Participation   PR Newswire
Sep 1, 2020
04:05PM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Aug 31, 2020
07:04AM EDT  Karyopharm Therapeutics Appoints Christy Oliger To Board   RTTNews
07:01AM EDT  Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors   PR Newswire
Aug 25, 2020
08:37AM EDT  Cramer Gives His Opinion On Linde, Barrick Gold And More   Benzinga
Aug 21, 2020
08:01AM EDT  Karyopharm's Founder, Sharon Shacham, PhD, Selected as a Finalist for the EY   PR Newswire
Aug 10, 2020
08:02AM EDT  Kaskela Law LLC Announces Investigation of Karyopharm Therapeutics Inc. (KPTI)   PR Newswire
Aug 4, 2020
10:19AM EDT  SVB Leerink Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $30   Benzinga
07:18AM EDT  Karyopharm Therapeutics Q2 EPS $(0.63) Misses $(0.58) Estimate, Sales $33.51M Beat $27.42M Estimate   Benzinga
07:09AM EDT  Karyopharm Therapeutics Q2 Net Loss $46.4 Mln Or $0.63/shr Vs. Net Loss $43.4 Mln Or $0.71/shr Last Year   RTTNews
07:01AM EDT  Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent   PR Newswire
05:19AM EDT  Earnings Scheduled For August 4, 2020   Benzinga
Aug 3, 2020
04:06PM EDT  Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule   PR Newswire
Jul 28, 2020
07:01AM EDT  Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020   PR Newswire
Jul 20, 2020
07:23AM EDT  Karyopharm: FDA Accept SNDA For XPOVIO For Patients With Multiple Myeloma After At Least One Prior Line Of Therapy   RTTNews
07:06AM EDT  Karyopharm Announces FDA Acceptance Of Supplemental New Drug Application For XPOVIO As A Treatment For Patients With Multiple Myeloma After At Least One Prior Line of Therapy   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC